Bluebird Bio receives an acquisition offer from Ayrmid Ltd, signaling potential changes in the company's future.
BeiGene's Tevimbra receives positive CHMP opinion as a first-line treatment for extensive-stage small cell lung cancer.
TriClip system offers substantial and sustained improvements in tricuspid regurgitation severity after two years.